CDKN2B and prostate carcinoma: Single‐nucleotide polymorphisms (SNPs) of the lncRNA cyclin‐dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B‐AS1) have been associated with the risk and progression of various cancers; however, their role in prostate cancer (PCa) remains underexplored.